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Abstract
Defects of platelet intracellular signaling can result in severe platelet dysfunction. Several muta-
tions in each of the linked genes FERMT3 and RASGRP2 on chromosome 11 causing a Glanzmann-
like bleeding phenotype have been identified so far. We report on novel variants in two unrelated
pediatric patients with severe bleeding diathesis—one with leukocyte adhesion deficiency type
III due to a homozygous frameshift in FERMT3 and the other with homozygous variants in both,
FERMT3 and RASGRP2. We focus on the challenging genetic and functional variant assessment
and aim to accentuate the risk of obtaining misleading results due to the phenomenon of genetic
linkage.
K EYWORD S
bleeding disorders other than hemophilia, hematology, hemostasis and thrombosis, platelet
disorders
1 INTRODUCTION
Glanzmann thrombasthenia (GT) is a rare inherited platelet disorder
caused by homozygous or compound-heterozygous pathogenic vari-
ants in the ITGA2B or ITGB3 genes leading to either absent expres-
sion or dysfunction of integrin 𝛼IIb𝛽3 on human platelets.
1 However,
mutations in the signaling molecules of platelets can lead to a simi-
lar bleeding phenotype. Since 2008, 15 homozygous, mainly stop-gain
pathogenic variants in FERMT3 have been identified to account for a
complete abrogation of Kindlin-3 expression, a subcellular focal adhe-
sion protein that binds to the cytoplasmic tail of integrins, and hence,
physiologically increases their stability and ligand affinity especially
Abbreviations: CalDAG-GEFI, calcium and diacylglycerol-regulated guanine exchange factor I; GT, Glanzmann thrombasthenia; LAD, leukocyte adhesion deficiency; Rap1, Ras-related protein 1;
TRAP6, thrombin receptor activating peptide 6.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any
medium, provided the original work is properly cited and is not used for commercial purposes.
c© 2019 The Authors. Pediatric Blood & Cancer Published byWiley Periodicals, Inc.
in neutrophils and platelets.2–11 The clinical phenotype of leukocyte
adhesion deficiency (LAD) type III (LAD-III), formerly also classified
as LAD type 1 variant (LAD-1/v) by Kuijpers et al, is characterized
by early onset of recurrent nonpussing bacterial or fungal infections,
a severe bleeding diathesis similar to that of GT, and, inconstantly,
osteopetrosis.12
The calcium and diacylglycerol-regulated guanine exchange factor
I (CalDAG-GEFI) has been proven to be a critical molecule regulating
rapid Ca2+-dependent platelet activation by stimulating the GTP load
of Ras-related protein 1 (Rap1), a central molecular switch that drives
integrin-mediated platelet aggregation and granule release.13 In 2014,
Canault et al provided the first evidence that ahomozygouspathogenic
Pediatr Blood Cancer. 2020;67:e28078. wileyonlinelibrary.com/journal/pbc 1 of 5
https://doi.org/10.1002/pbc.28078
2 of 5 MANUKJAN ET AL
variant in the CalDAG-GEFI encoding RASGRP2 gene caused a severe
mucocutaneous bleeding disorder with impaired platelet, but nor-
mal neutrophil function in three affected siblings.14 Until now, 20
homozygous or compound-heterozygous pathogenic variants in RAS-
GRP2 have been described.15,16 In this report, we demonstrate that
novel variants inFERMT3andRASGRP2, bothonchromosome11q13.1,
maymislead variant assessment due to genetic linkage in patients sup-
posed to have LAD-III or platelet-type bleeding disorder 18.
2 RESULTS
2.1 Clinical symptoms and phenotype
Index patient 1.II.5 is the fifth child of asymptomatic Libyan parents
who reportednot tobeconsanguineous (Figure1A). Theeldest brother
died at the age of 7 days due to neonatal sepsis, whereas the younger
three siblings are healthy. The 4-year-old female patient with failure to
thrive had a marked history of frequent mucocutaneous bleeding ten-
dency, predominantly epistaxis, gum bleedings, and hematomas. After
surviving neonatal sepsis, she suffered from recurrent nonpussing bac-
terial infections and chronic anemia, aggravated by repetitive acute
blood loss, which regularly demanded antibiotic treatment and red
blood cell transfusions. Severe bleeding episodes could hardly be over-
come by tranexamic acid or desmopressin, but always terminated after
platelet transfusion. She successfully underwent matched unrelated-
donor hematopoietic stem cell transplantation at the age of 9 years
following myeloablative conditioning with thiotepa (8 mg/kg), treo-
sulfan (42 g/m2), fludarabine (150 mg/m2), and antithymocyte globu-
lin (60 mg/kg). Prophylaxis of graft-versus-host disease was provided
with methotrexate and cyclosporine A. Neutrophil engraftment was
recorded at day 18 leading to discharge of the patient at day 34. Under
complete donor chimerism, neither bacterial infections nor bleeding
episodes occurred, and spleen size declined significantly.
The 15-year-old female index patient 2.II.2 is the second child of
asymptomatic, consanguineous parents (first-degree cousins) originat-
ing from Turkey (Figure 1B). Since early childhood, she suffered from a
pronouncedmucocutaneous bleeding tendency, in particular epistaxis,
gum bleedings, hematomas, and prolonged menstrual hemorrhage.
An adenoidectomy and a surgical abscess incision were complicated
by diffuse postinterventional bleeding. The patient repetitively needs
oral or even intravenous iron substitution due to secondary iron
deficiency anemia. Perimenstrual treatment with tranexamic acid or
desmopressin did not lead to significant improvement of the bleeding
tendency. Recommended prophylaxis with an oral contraceptive to
reduce menstrual bleeding episodes has been refused by her parents
so far. The elder sister, 2.II.1, reported prolonged menstrual bleedings
without additional bleeding symptoms.
2.2 Laboratory findings and functional assays
Accessible main laboratory findings of the investigated index patients
and family members are summarized in Table 1. In all the investigated
individuals, the platelet count and mean platelet volume were normal.
The whole blood count of patient 1.II.5 showed marked leukocytosis
with an elevated neutrophil count. PFA-100 R© (platelet function ana-
lyzer) closure times and light transmission aggregometry were signifi-
cantly pathologic in both index patients and, to amilder extent, in other
members of family 2, while von Willebrand and plasmatic coagulation
factors were normal. Anemia was consistent with blood loss and sec-
ondary iron deficiency. Slightly reduced factor XI activitywas recorded
for two individuals.
For both index patients, flow cytometric analysis of platelets proved
normal expression of integrins 𝛼IIb (CD41a) and 𝛽3 (CD61), which
form the fibrinogen receptor (Table 1), of the von Willebrand recep-
tor GPIb/V/IX, and of the other investigated platelet receptors (data
not shown).17 However, conformational change, and thus, activation
of 𝛼IIb𝛽3 detected by PAC-1 antibody binding was diminished in both
index patients upon low- (2 µM) and optimal-dose (5 µM) adenosine
diphosphate (ADP) as well as thrombin receptor activating peptide
6 (TRAP6) treatment, though to a lesser extent (Figure 1C; data not
shown). In contrast, P-selectin (CD62P) neo-expression upon TRAP6
was not impaired in patient 1.II.5 (data not shown), whereas CD62P
neo-expression upon ADP treatment was clearly, and upon TRAP6
treatment, slightly reduced in patient 2.II.2 (Figure 1C).
2.3 Genetic analysis and variant assessment
Since the clinical phenotype and the functional assays suggested
Kindlin-3 deficiency in patient 1.II.5, we sequenced the coding region
of FERMT3 (NM_178443.2) and found a novel homozygous variant,
c.1185delT (p.D397Tfs*29), leading to a premature stop codon and
intracellular lack of the truncated protein (Figure 1D). Both parents
1.II.1 and1.II.2were heterozygous for thedetected variant (Figures 1A
and 1D). No variant was discovered in RASGRP2 (NM_153819.1) (data
not shown).
In patient 2.II.2, we identified two homozygous variants in FERMT3
and RASGRP2 by targeted next generation sequencing, as previously
described.18 Both variants were confirmed by Sanger sequencing
(Figure 1E). The novel missense variant c.119C > T (p.S40L) in
FERMT3, classified as a variant of unknown significance after apply-
ing in silico prediction tools (MutationTaster2: polymorphism; sort-
ing intolerant from tolerant [SIFT]: tolerated; Polyphen-2: benign),
cosegregated with the clinical phenotype in family 2 (Figures 1B
and 1E). The variant c.742G > C (p.G248R) in RASGRP2 is a novel
variant affecting the same amino acid position as that in a previ-
ously reported distinct missense variant (p.G248W).14 After apply-
ing in silico prediction tools (MutationTaster2: disease causing; SIFT:
deleterious; Polyphen-2: probably damaging) and proving cosegre-
gation in family 2, we classified this variant as likely pathogenic
(Figures 1B and 1E).
We then verified the functional impact of the detected variants
on intracellular platelet signaling in the two index patients by Rap1
pull-down assays, as previously reported.13 Normal Rap1 activation
upon ADP and thrombin treatment confirmed functional signaling
in patient 1.II.5. In contrast, ADP treatment showed absent Rap1
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F IGURE 1 Functional and genetic evaluation of both index patients with Glanzmann-like bleeding diathesis; pedigrees of family 1 (A) and
family 2 (B) with the corresponding index patients (arrows) and detected variants in FERMT3 (A, B) or RASGRP2 (B); (C) flow cytometric analysis of
resting and activated platelets after ADP and thrombin receptor activating peptide 6 (TRAP6) treatment (in µM) analyzing P-selectin (CD62P)
neo-expression and activated fibrinogen receptor (PAC-1 antibody); (D) Sanger sequencing of the one-nucleotide deletion in FERMT3 in index
patient 1.II.5 (homozygous) and her parents 1.I.1 and 1.I.2 (each heterozygous); abrogation of Kindlin-3 in index patient 1.II.5, detected bywestern
blot (beta-tubulin as loading control); (E) Sanger sequencing to confirm homozygous variants in FERMT3 (left) and RASGRP2 (right) in index patient
2.II.2 and heterozygous segregation in family 2 (exemplarily shown for 2.I.1). (F) Rap1 pull-down assays with resting and activated platelets from
index patients 1.II.5 and 2.II.2 after treatment with ADP (in µM) and thrombin (U/mL); Rap1was detected by anti-Rap1 antibody. (G) Schematic
depiction of the genetic linkage of FERMT3 and RASGRP2 on chromosome 11with five further genes encoded in the genomic region in between
(black boxes); abbreviations: HC, healthy control; het, heterozygous; hom, homozygous; Thr, thrombin
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TABLE 1 Main laboratory parameters of the investigated index patients and family members
Family 1 Family 2
Parametersa
Normal
range
Patient
(1.II.5)
Patient
(2.II.2)
Sister
(2.II.1)
Sister
(2.II.3)
Mother
(2.I.2)
Whole blood count
Leukocyte count (nL−1) 4.5-13.0 23.39 8.64 7.76 8.72 8.45
Neutrophils (%) 36.0-72.0 66.0 61.9 66.1 52.9 70.0
Hemoglobin (g/dL) 12.0-16.0 8.2 9.6 11.5 12.6 12.2
MCV (fL) 78.0-95.0 78.0 72.6 69.3 75.7 84.2
Platelet count (nL−1) 150-450 189 272 223 214 190
MPV (fL) 7.0-11.0 11.0 9.1 8.4 7.9 9.0
Coagulation factor activities
Factor XI (%) 70-120 75 62 n. d. 61 n. d.
vWF antigen (%) 60-200 61 109 187 135 170
vWF activity (%) 50-180 82 131 158 143 154
PFA-100 R© closure times
Col/Epi (s) 84-160 >300 >300 257 119 189
Col/ADP (s) 68-121 >300 231 116 71 94
Born aggregometryb
ADP 4 µmol/L Normal n. a. ↓↓ ↓↓ ↓ ↓↓
ADP 20 µmol/L Normal n. a. ↓ ↓ n. d. ↓
Epinephrine 8 µmol/L Normal n. a. ↓↓ ↓↓ ↓↓ ↓↓
Epinephrine 40 µmol/L Normal n. a. ↓↓ ↓↓ n. d. ↓↓
Collagen 1 µg/mL Normal n. a. ↓ Normal ↓ Normal
Collagen 2 µg/mL Normal n. a. Normal n. d. Normal n. d.
Ristocetin 1.0mg/mL Normal n. a. ↓↓ ↓↓ ↓↓ ↓↓
Ristocetin 1.5mg/mL Normal n. a. Normal Normal Normal Normal
Flow cytometry
CD41a expression Normal Normal Normal n. d. n. d. n. d.
CD61 expression Normal Normal Normal n. d. n. d. n. d.
Abbreviations: ADP, adenosine diphosphate; Col/ADP, collagen/ADP cartridge; Col/Epi, collagen/epinephrine cartridge; MCV, mean corpuscular volume;
MPV, mean platelet volume; n. a., not available; n. d., not determined; PFA, platelet function analyzer; vWF, vonWillebrand factor.
aResults outside the reference range are expressed in bold numbers or symbols.
bResults from at least two independent aggregation analyses are depicted. Aggregation curve assessment: normal (maximal aggregation>80%, aggregation
>20%before 6min, disaggregation<20%), ↓= intermediate (maximal aggregation 60-80%), ↓↓= pathologic (maximal aggregation<60%, aggregation<20%
after 6min and/or disaggregation≥20%).
activation in patient 2.II.2, and hence, proved specifically impaired
CalDAG-GEFI-mediated signaling (Figure 1F).13 With these results,
we considered the RASGRP2 variant as causative in 2.II.2.
3 DISCUSSION
In this study, we describe a novel single nucleotide deletion variant in
FERMT3 in a 4-year-old femalewith LAD-III, and detected a novel likely
pathogenic variant in RASGRP2 in a female adolescent with a platelet-
type bleeding disorder 18. We especially aim to underline the neces-
sity for comprehensive diagnostic exploration of patients with similar
severe bleeding diathesis, but distinct alteration of intracellular signal-
ing, and to emphasize the pitfall of misleading variant interpretation
due to chromosomal linkage of the affected genes (Figure 1G). In 2007,
several partly conflicting reports on the role ofCalDAG-GEFI andRap1
in impaired integrin activation opened a research field for these signal-
ing molecules.12,13,19 Likely due to the linkage disequilibrium, identifi-
cation of the defective intracellular signaling molecule in LAD-III was
controversially discussed. It remains unevaluated whether individual
2.II.1 in family 2 shows mild bleeding symptoms due to two heterozy-
gous hits in the signaling pathway.
Although LAD-III can be differentiated from RASGRP2-associated
platelet-type bleeding disorder 18 to a certain degree by marked
leukocytosis and profoundly impaired neutrophil function, a clear
distinction may not always be possible in daily clinical routine due
to overlapping clinical phenotypes or restricted access to compre-
hensive functional platelet assays. Since current guidelines suggest
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high-throughput sequencing techniques early in the diagnostic algo-
rithm for inherited platelet function disorders,20 we recommend
careful assessment of the closely linked genes FERMT3 and RASGRP2
in context with a Glanzmann-like bleeding disorder.
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